Cristina Ramo‐Tello

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 896 citations

Neurological Disorder, Clinical Neurology, Clinical Trials +9

Defining secondary progressive multiple sclerosis

Johannes Lorscheider, Katherine Buzzard, Vilija Jokubaitis et al. · Brain · 2016 · 401 citations · Full text

Neurological Disorder, Disability, Clinical Neurology +22

Defining reliable disability outcomes in multiple sclerosis

Tomáš Kalinčík, Gary Cutter, Tim Spelman et al. · Brain · 2015 · 223 citations · Full text

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Tomáš Kalinčík, J William L Brown, Neil P. Robertson et al. · The Lancet Neurology · 2017 · 157 citations · Full text

Disease Progression, Medicine, Systemic Treatment +9

Neuromyelitis optica spectrum disorders

María Sepúlveda, Thaís Armangué, Núria Solà‐Valls et al. · Neurology Neuroimmunology & Neuroinflammation · 2016 · 148 citations · Full text